Inhibition of breast and brain cancer cell growth by BCCIPα, an evolutionarily conserved nuclear protein that interacts with BRCA2

被引:80
|
作者
Liu, JM
Yuan, Y
Huan, J
Shen, ZY
机构
[1] Univ New Mexico, Hlth Sci Ctr, Dept Mol Genet & Microbiol, Albuquerque, NM 87131 USA
[2] Univ Illinois, Coll Med, Grad Program Mol Genet, Chicago, IL 60607 USA
关键词
BRCA2; calcium-binding protein; BCCIP;
D O I
10.1038/sj.onc.1204098
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
BRCA2 is a tumor suppressor gene involved in mammary tumorigenesis, Although important functions have been assigned to a few conserved domains of BRCA2, little is known about the longest internal conserved domain encoded by exons 14-24.,We identified a novel protein, designated BCCIP alpha, that interacts with part of the internal conserved region of human BRCA2, Human BCCIP represents a family of proteins that are evolutionarily conserved, and contain three distinct domains: an N-terminus acidic domain (NAD) of 30-60 amino acids, an internal conserved domain (ICD) of 180-220 amino acids, and a C-terminus variable domain (CVD) of 30-60 amino acids, The N-terminal half of the human BCCIP ICD shares moderate homology with regions of calmodulin and ill-calpain, suggesting that BCCIP may also bind Ca. Human cells express both a longer, BCCIP alpha, and a shorter, BCCIP beta, form of the protein, which differ in their CVD, BCCIP is a nuclear protein highly expressed in testis, Although BCCIP beta expression is relatively consistent in cancer cells, the expression of BCCIP alpha varies in cancer cell Lines. The BCCIP alpha gene is located at chromosome 10q25.3-26.2, a region frequently altered in brain and other cancers. Furthermore, expression of BCCIP alpha inhibits breast and brain cancer cell growth,but fails to inhibit HT1080 cells and a non-transformed human skin fibroblast, These results suggest that BCCIP alpha is an important cofactor for BRCA2 in tumor suppression.
引用
收藏
页码:336 / 345
页数:10
相关论文
共 50 条
  • [41] Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers
    Neuhausen, Susan L.
    Brummel, Sean
    Ding, Yuan Chun
    Singer, Christian F.
    Pfeiler, Georg
    Lynch, Henry T.
    Nathanson, Katherine L.
    Rebbeck, Timothy R.
    Garber, Judy E.
    Couch, Fergus
    Weitzel, Jeffrey
    Narod, Steven A.
    Ganz, Patricia A.
    Daly, Mary B.
    Godwin, Andrew K.
    Isaacs, Claudine
    Olopade, Olufunmilayo I.
    Tomlinson, Gail
    Rubinstein, Wendy S.
    Tung, Nadine
    Blum, Joanne L.
    Gillen, Daniel L.
    BREAST CANCER RESEARCH, 2009, 11 (05):
  • [42] The role of PCID2 and Centrin2 in nuclear export and centrosomal localization of BRCA1/BRCA2 in Hs578t breast cancer cells
    Turturice, L.
    Polio, N.
    Gatesman, T.
    Resendes, K.
    MOLECULAR BIOLOGY OF THE CELL, 2023, 34 (02) : 185 - 186
  • [43] Generation of two induced pluripotent stem cell lines from breast cancer patients carrying BRCA2 variants
    Zhang, Mao
    Liu, Wenqiang
    Li, Audrey
    Htet, Min H.
    Yu, Rebecca
    Telli, Melinda L.
    Wu, Joseph C.
    STEM CELL RESEARCH, 2023, 72
  • [44] Tumor Growth Inhibition by Olaparib in BRCA2 Germline-Mutated Patient-Derived Ovarian Cancer Tissue Xenografts
    Kortmann, Ursula
    McAlpine, Jessica N.
    Xue, Hui
    Guan, Jun
    Ha, Gavin
    Tully, Sophie
    Shafait, Sharaz
    Lau, Alan
    Cranston, Aaron N.
    O'Connor, Mark J.
    Huntsman, David G.
    Wang, Yuzhuo
    Gilks, C. Blake
    CLINICAL CANCER RESEARCH, 2011, 17 (04) : 783 - 791
  • [45] DNA microarray profiling of BRCA1 and BRCA2 deficient human tumors and cell-lines using a breast cancer specific platform
    Mulligan, Jude
    Farztdinov, Vadim
    Halfpenny, Iris
    Delaney, Thomas
    Tanney, Austin
    Oliver, Gavin
    Quinn, Jennifer
    Couch, Fergus
    Harkin, Paul
    Kerr, Peter
    Kennedy, Richard
    CANCER RESEARCH, 2009, 69
  • [46] Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer
    Weigelt, Britta
    Comino-Mendez, Inaki
    de Bruijn, Ino
    Tian, Lei
    Meisel, Jane L.
    Garcia-Murillas, Isaac
    Fribbens, Charlotte
    Cutts, Ros
    Martelotto, Luciano G.
    Ng, Charlotte K. Y.
    Lim, Raymond S.
    Selenica, Pier
    Piscuoglio, Salvatore
    Aghajanian, Carol
    Norton, Larry
    Murali, Rajmohan
    Hyman, David M.
    Borsu, Laetitia
    Arcila, Maria E.
    Konner, Jason
    Reis-Filho, Jorge S.
    Greenberg, Roger A.
    Robson, Mark E.
    Turner, Nicholas C.
    CLINICAL CANCER RESEARCH, 2017, 23 (21) : 6708 - 6720
  • [47] Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants
    Li, Hongyan
    Engel, Christoph
    de la Hoya, Miguel
    Peterlongo, Paolo
    Yannoukakos, Drakoulis
    Livraghi, Luca
    Radice, Paolo
    Thomassen, Mads
    Hansen, Thomas V. O.
    Gerdes, Anne-Marie
    Nielsen, Henriette R.
    Caputo, Sandrine M.
    Zambelli, Alberto
    Borg, Ake
    Solano, Angela
    Thomas, Abigail
    Parsons, Michael T.
    Antoniou, Antonis C.
    Leslie, Goska
    Yang, Xin
    Chenevix-Trench, Georgia
    Caldes, Trinidad
    Kwong, Ava
    Pedersen, Inge Sokilde
    Lautrup, Charlotte K.
    John, Esther M.
    Terry, Mary Beth
    Hopper, John L.
    Southey, Melissa C.
    Andrulis, Irene L.
    Tischkowitz, Marc
    Janavicius, Ramunas
    Boonen, Susanne E.
    Kroeldrup, Lone
    Varesco, Liliana
    Hamann, Ute
    Vega, Ana
    Palmero, Edenir, I
    Garber, Judy
    Montagna, Marco
    Van Asperen, Christi J.
    Foretova, Lenka
    Greene, Mark H.
    Selkirk, Tina
    Moller, Pal
    Toland, Amanda E.
    Domchek, Susan M.
    James, Paul A.
    Thorne, Heather
    Eccles, Diana M.
    GENETICS IN MEDICINE, 2022, 24 (01) : 119 - 129
  • [48] Epidermal Growth Factor Receptor Targeting Peptide Nanoparticles Simultaneously Deliver Gemcitabine and Olaparib to Treat Pancreatic Cancer With Breast Cancer 2 (BRCA2) Mutation
    Du, C.
    Wang, Y.
    Tian, X.
    Nie, G.
    Yang, Y.
    PANCREAS, 2019, 48 (10) : 1422 - 1422
  • [49] DHX9 inhibition as a novel therapeutic for ovarian and breast cancer with loss-of-function mutations in the DNA damage repair genes BRCA1 or BRCA2
    Castro, Jennifer
    Daniels, Matthew H.
    Pai, Sunaina
    Laidlaw, Monique
    Wu, Jie
    Brennan, David
    Johnston, Brian T.
    Raman, Anugraha
    Lu, Chuang
    Blakemore, Stephen J.
    Silver, Serena J.
    Boriack-Sjodin, P. Ann
    Duncan, Kenneth W.
    Sager, Jason A.
    Copeland, Robert A.
    CANCER RESEARCH, 2024, 84 (01)
  • [50] Evaluation of the diagnostic accuracy of the stop codon (SC) assay for identifying protein-truncating mutations in the BRCA1 and BRCA2 genes in familial breast cancer
    M. Sakayori
    M. Kawahara
    K. Shiraishi
    T. Nomizu
    A. Shimada
    T. Kudo
    R. Abe
    N. Ohuchi
    S. Takenoshita
    R. Kanamaru
    C. Ishioka
    Journal of Human Genetics, 2003, 48 : 130 - 137